Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high, (99.6%), while the 30-day mortality rate, (3.4%) and the one year rate, (18.2%) was acceptable. Annual mortality was more pronounced in those patients with a EuroSCORE greater than 20%, (76.3% vs.…
PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.
Summary: Randomized, open, pragmatic essay PROTECT (patient related outcomes of Endeavor versus Cypher stenting trial) compared two drug-eluting stents with different behaviors, (Cypher ® and Endeavor ®), in the reendothelialization degree and antiproliferative potency. Cypher has a permanent sirolimus-eluting polymer which generates a potent antiproliferative effect and a suboptimal healing (or reendothelialization). Furthermore, Endeavor has…
IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.
IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. Holger Thiele2012-08-26 Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock
FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.
Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted a reduction in the age of presentation, especially in women under 60 years with increased incidence of smoking and obesity. Pain-center time was significantly reduced, while increasing the number of patients…
GARY: German Aortic Valve Registry.
Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant in 2011 were included. As recommended in the European Cardiovascular Guidelines, this national registry suggests that percutaneous implant represents the dominant treatment of this disease, especially in high-risk patients. In high-risk…
GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration of omega-3 and insulin glargine and their benefits in reducing atherosclerosis progression. Conducted at 32 centers in 7 countries, this study included 1,092 individuals with hyperglycemia and increased risk of cardiovascular…